These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29346119)

  • 1. The role of tedizolid in skin and soft tissue infections.
    Bouza E; Muñoz P; Burillo A
    Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of tedizolid for the treatment of MRSA infections.
    Hall RG; Smith WJ; Putnam WC; Pass SE
    Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tedizolid: a service evaluation in a large UK teaching hospital.
    York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
    Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
    Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Action in nosocomial pneumonia and severe skin and soft tissue infections. Linezolid in treatment].
    Bodmann KF
    Pharm Unserer Zeit; 2004; 33(1):38-41. PubMed ID: 14968711
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
    Lodise TP; Fang E; Minassian SL; Prokocimer PG
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. tedizolid (SIVEXTRO*) in skin and soft-tissue infections.
    Prescrire Int; 2017 Mar; 26(180):63-64. PubMed ID: 30730618
    [No Abstract]   [Full Text] [Related]  

  • 15. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
    Kanafani ZA; Corey GR
    Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.
    Carena AA; Stryjewski ME
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.
    Chahine EB; Sucher AJ; Knutsen SD
    Consult Pharm; 2015 Jul; 30(7):386-94. PubMed ID: 26173190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.